PT  - JOURNAL ARTICLE
AU  - Rockett, Rebecca J
AU  - Draper, Jenny
AU  - Gall, Mailie
AU  - Sim, Eby M
AU  - Arnott, Alicia
AU  - Agius, Jessica E
AU  - Johnson-Mackinnon, Jessica
AU  - Martinez, Elena
AU  - Drew, Alexander P
AU  - Lee, Clement
AU  - Ngo, Christine
AU  - Ramsperger, Marc
AU  - Ginn, Andrew N
AU  - Wang, Qinning
AU  - Fennell, Michael
AU  - Ko, Danny
AU  - Huston, Linda
AU  - Kairaitis, Lukas
AU  - Holmes, Edward C
AU  - O’Sullivan, Matthew N
AU  - Chen, Sharon C-A
AU  - Kok, Jen
AU  - Dwyer, Dominic E
AU  - Sintchenko, Vitali
TI  - Co-infection with SARS-COV-2 Omicron and Delta Variants Revealed by Genomic Surveillance
AID  - 10.1101/2022.02.13.22270755
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.02.13.22270755
4099  - http://medrxiv.org/content/early/2022/02/15/2022.02.13.22270755.short
4100  - http://medrxiv.org/content/early/2022/02/15/2022.02.13.22270755.full
AB  - We identified the co-infection of the SARS-CoV-2 Omicron and Delta variants in two epidemiologically unrelated patients with chronic kidney disease requiring haemodialysis. Both SARS-CoV-2 variants were co-circulating locally at the time of detection. Amplicon- and probe-based sequencing using short- and long-read technologies identified and quantified Omicron and Delta subpopulations in respiratory samples from the two patients. These findings highlight the importance of genomic surveillance in vulnerable populations.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by the Prevention Research Support Program funded by the New South Wales Ministry of Health and the NHMRC Centre for Research Excellence in Emerging Infectious Diseases (GNT1102962). The funders of this study had no role in the study design, data collection, data analysis and interpretation, or writing of the report. The corresponding author had full access to study data and final responsibility for the decision to submit for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical and governance approval for the study was granted by the Western Sydney Local Health District Human Research Ethics Committee 2020/ETH02426 and 2020/ETH00786)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe SARS-CoV-2 genome sequencing data is available (with human reads removed) in the National Center for Biotechnology Information (NCBI) GenBank (BioProject PRJNA633948).